The clinical impact of nephrotoxicity in renal transplantation

Transplantation

Volumn 69, Issue 12 SUPPL., 2000, Pages

  Johnson, Robert W G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; TACROLIMUS;

CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; GRAFT SURVIVAL; INCIDENCE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PREVALENCE; PRIORITY JOURNAL; TISSUE INDUCTION;

EID: 0343962625     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200006271-00004     Document Type: Conference Paper

References (48)

1. Calne RY, Thiru S, McMaster P, et al. Cyclosporine A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2: 1323-1327.
2. Green CJ, Allison AC. Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporine-A treatment. Lancet 1978; 1(8075): 1181-1183.
3. Flechner SM. Cyclosporine: a new and promising immunosuppressive agent. Urol Clin North Am 1983; 10: 263-275.
4. Sibley RK, Rynasiewicz J, Ferguson RM, et al. Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone. Surgery 1983; 94: 225-234.
5. Canafax DM, Ascher NL. Cyclosporine immunosuppression. Clin Pharm 1983; 2: 515-524.
6. European Multicentre Trial Group. European multicentre trial of cyclosporine in renal transplantation: 10-year follow-up. Transplant Proc 1993; 25: 527-529.
7. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705.
8. Valdes RH, Sonora M. Nonimmunologic factors in the progression of chronic dysfunction in renal allografts. Transplant Proc 1999; 31: 2967-2969.
9. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56: 783-793.
10. Tilney NL. Chronic rejection and its risk factors. Transplant Proc 1999; 31(suppl 1/2A): 41S44S.
11. Kim ST, Lee S, Kim J, et al. Analysis of the factors affecting survival of renal transplant recipients. Transplant Proc 1998; 30: 3086-3087.
12. Ishikawa N, Tanabe K, Tokumoto T, et al. Risk factors affecting the long-term results of renal retransplantation. Transplant Proc 1999; 31: 2858-2859.
13. Solez H. International standardization of criteria for histologic diagnosis of chronic rejection in renal allografts. Clin Transplant 1994; 8(pt 2): 345-350.
14. Zietse R, Balk AH, Dorpel MA, et al. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994; 14: 1-5
15. Greenberg A, Thompson ME, Griffith BJ, et al. Cyclosporine nephrotoxicity in cardiac allograft patients-a seven-year follow-up. Transplantation 1990; 50: 589-593.
16. Tinawi M, Miller L, Bastard B. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center. Clin Transplant 1997; 11: 1-8.
17. Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation. Transplantation 1998; 66: 59-66.
18. Dieterle A, Gratwohl A, Nizze H, et al. Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients. Transplantation 1990; 49: 1093-1100.
19. Young EW, Ellis CN, Messana JM, et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporine. Kidney Int 1994; 46: 1216-1222.
20. Dimény E, Wahlberg J, Larsson E, et al. Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection? Clin Transplant 1995; 9: 79-84.
21. Rush DN, Jeffrey JR, Gough J. Sequential protocol biopsies in renal transplant patients. Transplantation 1995; 59: 511-514.
22. Isoniemi HM, Krogerus L, von Willebrand E, et al. Histopathological findings in well-functioning, long-term renal allografts. Kidney Int 1992; 41: 155-160.
23. Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998; 49: 356-363.
24. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. Transplantation 1998; 66: 1736-1740.
25. Porayko MK, Textor SC, Krom RA, et al. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994; 69: 105-111.
26. Chandraker A. Diagnostic techniques in the work-up of renal allograft dysfunction-an update. Curr Opin Nephrol Hypertens 1999; 8: 723-728.
27. Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 1995; 48(suppl 52): S63-S69.
28. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20 (suppl 3): 759-771.
29. Hughes DA. Fine-needle cytology in the monitoring of human renal allograft progress. Immunol Lett 1991; 29: 147-152.
30. De Gaetano AM, Boldrini G, Nanni G, et al. Noninvasive surveillance of allografted kidneys by ultrasonic duplex scanning. Angiology 1989; 40: 705-715.
31. Sens YAS, de Andrade RM, Bastos RM, et al. Duplex Doppler ultrasonography in the dysfunction of early renal allografts: correlation with renal histopathology. Transplant Proc 1999; 31: 3009-3010.
32. Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 1990; 36: 1510-1516.
33. Lindholm A. A prospective study of cyclosporine monitoring in renal transplantation. Transplant Proc 1990; 22: 1260-1263.
34. Ubhi CS, Woodhouse L, Guillou PJ, Giles GR. Nephrol Dial Transplant 1988; 3: 814-819.
35. Trull AK, Best NG, Tan KK, et al. Blood cyclosporine concentrations but not dose correlate with acute changes in renal function following heart and heart-lung transplantation. Ther Drug Monit 1992; 14: 275-280.
36. Corey HE. Urine cytology: an underused method to diagnose acute renal allograft rejection. Pediatr Nephrol 1997; 11: 226-230.
37. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996; 62: 364-370.
38. Perico N, Remuzzi G. Prevention of transplant rejection. Current treatment guidelines and future developments. Drugs 1997; 54: 533-570.
39. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110-115.
40. Halloran PF. Risk factors in renal transplantation and implications for immunosuppressive therapy. Transplant Proc 1999; 31: 351-352.
41. Grinyó JM. Progress with cyclosporine-sparing regimens. Transplant Proc 1999; 31(suppl 8A): 11S-16S.
42. Hueso M, Bover J, Serón D, et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998; 66: 1727-1731.
43. Eckhoff DE, McGuire BM, Frenette LR, et al. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65: 180-187.
44. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040-1046.
45. Sabeel A, Qunibi W, Alfurayh O, Meshari KA. Simultaneous development of Kaposi's sarcoma and lymphoma in a renal transplant recipient. Am J Kidney Dis 1998; 31: 706-709.
46. Brunner FP, Landais P, Selwood NH. Malignancies after renal transplantation: the EDTA-ERA registry experience. European dialysis and Transplantation Association-European Renal Association. Nephrol Dial Transplant 1995; 19(suppl 1): 74-80.
47. Thliveris JA, Solez K, Yatscoff RW. A comparison of the effects of rapamycin and cyclosporine on kidney and heart morpholoy in a rabbit heterotopic heart transplant model. Histol Histopathol 1995; 10: 417421.
48. Groth CG, Bäckman L, Morales JM, et al. Sirolomus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999; 67: 1036-1042.